Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following multiple ascending doses in patients with type 2 diabetes mellitus.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hua Medicine Limited

Criteria

Inclusion Criteria:

• Male and female subjects with type 2 diabetes

• Age: 18 to 65 years

• BMI: 20 to 29 kg/m2

• Mentally, physically and legally eligible to give informed consent.

• Willingness to adhere to the protocol requirement.

Exclusion Criteria:

• Subjects with type 1 diabetes

• Episodes of hypoglycemia

• Unstable cardiovascular diseases

• Hepatic diseases

• Kidney disease

• Mental or central nervous system diseases

• Clinical abnormal findings in ECG, labs and physical exams